Study guide

2.3 Withdrawal Severity Rating Scales: CIWA-Ar & COWS

Certified Addictions Registered Nurse CARN

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Exam Overview

1.1 CARN Exam Overview, Eligibility & Requirements 1.2 How to Use This Study Guide & Preparation Strategy

2 Chapter 2: Assessment & Screening

2.1 DSM-5-TR Substance Use Disorder Diagnostic Criteria & Severity Classification 2.2 Standardized Screening Tools: AUDIT, DAST-10, CAGE, CRAFFT & ASSIST 2.3 Withdrawal Severity Rating Scales: CIWA-Ar & COWS 2.4 Neonatal & Special Population Assessment: Finnegan, Eat-Sleep-Console & Life Stages 2.5 Assessment of Co-Occurring Psychiatric & Medical Disorders

3 Chapter 3: Planning & Intervention

3.1 ASAM Criteria & Continuum of Placement Care 3.2 Motivational Interviewing (OARS) & Transtheoretical Stages of Change 3.3 Trauma-Informed Care Principles & Addictions Nursing Practice 3.4 Family Dynamics, Codependency, CRAFT Model & Family Support Systems 3.5 Nursing Diagnosis, Outcome Identification & Individualized Addictions Care Planning

4 Chapter 4: Clinical Management & Pharmacotherapy

4.1 Alcohol Withdrawal Syndrome Management & Complication Prevention 4.2 Opioid Withdrawal Management & Symptom-Triggered Protocols 4.3 Medications for Opioid Use Disorder (MOUD: Methadone, Buprenorphine & Extended-Release Naltrexone) 4.4 Pharmacotherapy for Alcohol & Nicotine Use Disorders 4.5 Harm Reduction Strategies: Naloxone, Fentanyl Test Strips & Syringe Services 4.6 Pain Management in Patients with Substance Use Disorders

5 Chapter 5: Substance-Specific Disorders, Prevention & Patient Education

5.1 Stimulant Use Disorders: Cocaine, Amphetamines & Caffeine 5.2 Sedative, Hypnotic, Anxiolytic & Gabapentinoid Misuse 5.3 Cannabis & Hallucinogen Use Disorders 5.4 Tobacco Use Disorder, Vaping & Cessation Interventions 5.5 Prevention, Brief Intervention, Patient Education & Behavioral Addictions

6 Chapter 6: Evaluation, Recovery & Continuing Care

6.1 Relapse Prevention Models: Marlatt's Model, Urge Surfing & High-Risk Situations 6.2 Mutual-Help Groups & Peer Recovery Support: 12-Step, SMART Recovery & Peer Specialists 6.3 Recovery Capital, Social Determinants of Health & Holistic Wellness 6.4 Transitions of Care, Discharge Planning & Long-Term Recovery Management

7 Chapter 7: Professional Role, Ethics & Legal Issues

7.1 ANA/IntNSA Scope & Standards of Addictions Nursing Practice 7.2 Confidentiality Laws: 42 CFR Part 2 vs. HIPAA & 2024 Alignment Updates 7.3 Legal & Ethical Issues, Stigma Reduction & Person-First Language

2.3 Withdrawal Severity Rating Scales: CIWA-Ar & COWS

Key Takeaways Explain This Topic AI

CIWA-Ar (Clinical Institute Withdrawal Assessment for Alcohol, Revised) assesses 10 clinical items; max score 67 (<8 mild, 8–14 moderate, ≥15 severe, indicating high risk for delirium tremens and seizures).

Symptom-triggered benzodiazepine administration based on serial CIWA-Ar scores achieves superior clinical outcomes with lower total medication dosage compared to fixed-schedule taper regimens.

COWS (Clinical Opiate Withdrawal Scale) evaluates 11 objective and subjective parameters; scores 5–12 indicate mild withdrawal, 13–24 moderate, 25–36 moderately severe, and >36 severe withdrawal.

Buprenorphine induction MUST be delayed until the patient reaches moderate opioid withdrawal (COWS score ≥8–12) to avoid precipitating severe agonist-displacement withdrawal.

CIWA-Ar requires full patient communication and cannot be accurately scored in uncommunicative, intubated, or severely delirious patients; objective vital sign monitoring must guide care in uncommunicative states.

Last updated: August 2026

  • Withdrawal Severity Rating Scales: CIWA-Ar & COWS
  • Physiology of Alcohol and Opioid Withdrawal

Acute withdrawal management is one of the most critical responsibilities of the Certified Addictions Registered Nurse (CARN). Withdrawal syndromes occur when chronic administration of a central nervous system (CNS) depressant or agonist is abruptly reduced or discontinued.

Alcohol Withdrawal: Chronic alcohol consumption causes neuroadaptation by enhancing inhibitory gamma-aminobutyric acid (GABA-A) receptor activity and down-regulating excitatory N-methyl-D-aspartate (NMDA) glutamate receptors. Sudden cessation results in GABA hypofunction and uninhibited NMDA glutamate excitation, manifesting as autonomic hyperactivity, tremors, seizures, and potentially fatal Delirium Tremens (DTs) .

Opioid Withdrawal: Chronic opioid exposure down-regulates endogenous mu-opioid receptor signaling and up-regulates intracellular cyclic adenosine monophosphate (cAMP) in the locus coeruleus. Cessation causes massive noradrenergic output, producing severe physical discomfort (sweating, rhinorrhea, lacrimation, severe abdominal cramping, diarrhea, piloerection, and intense agitation).

To standardize assessment and guide titration of pharmacotherapy, addictions nursing relies on validated rating scales: the CIWA-Ar for alcohol and the COWS for opioids.

CIWA-Ar: Alcohol Withdrawal Assessment Protocol

The Clinical Institute Withdrawal Assessment for Alcohol, Revised (CIWA-Ar) is a validated 10-item rating scale measuring the severity of alcohol withdrawal. Nine of the ten items are scored from 0 to 7; Orienting and clouding of sensorium is scored from 0 to 4. The maximum cumulative score is 67 .

Detailed CIWA-Ar 10-Item Scoring Table

Item Parameter Scoring Scale Range Clinical Features Evaluated by Nurse

Nausea and Vomiting 0 – 7 0 = None; 1 = Mild nausea/no vomiting; 4 = Intermittent nausea; 7 = Constant nausea, dry heaves, and vomiting.

Tremor 0 – 7 Evaluated with arms extended and fingers spread. 0 = No tremor; 1 = Not visible, felt fingertip-to-fingertip; 4 = Moderate with arms extended; 7 = Severe, even with arms non-extended.

Paroxysmal Sweats 0 – 7 0 = No sweat; 1 = Barely perceptible moisture; 4 = Beads of sweat obvious on forehead; 7 = Drenching sweats.

Anxiety 0 – 7 0 = None; 1 = Mildly anxious; 4 = Moderate anxiety/guarded; 7 = Acute panic state.

Agitation 0 – 7 0 = Normal activity; 1 = Somewhat normal activity; 4 = Moderately fidgety/restless; 7 = Paces constantly, thrashes about.

Tactile Disturbances 0 – 7 0 = None; 1 = Very mild itching/burning/numbness; 4 = Moderate hallucinations/pins & needles; 7 = Continuous tactile hallucinations.

Auditory Disturbances 0 – 7 0 = None; 1 = Mild harshness/frightening sounds; 4 = Moderate hallucinations; 7 = Continuous auditory hallucinations.

Visual Disturbances 0 – 7 0 = None; 1 = Mild sensitivity to light; 4 = Moderate hallucinations; 7 = Continuous visual hallucinations.

Headache, Fullness in Head 0 – 7 0 = None; 1 = Very mild; 4 = Moderate; 7 = Extremely severe.

Orientation & Sensorium 0 – 4 0 = Oriented x4; 1 = Cannot do serial additions; 2 = Disoriented to date by <2 days; 3 = Disoriented to date by >2 days; 4 = Disoriented to person/place.

CIWA-Ar Score Stratification & Action Matrix CIWA-Ar Total Score Stratification:

  • < 8 --> Mild Withdrawal (Non-pharmacologic comfort, serial re-assessment q4h)
  • 8 - 14 --> Moderate Withdrawal (Symptom-triggered Benzodiazepine administration, re-assess q2h)
  • >= 15 --> Severe Withdrawal (High risk DTs/Seizures; Immediate Benzodiazepine, re-assess q1h)

Score < 8 (Mild): Low risk of complications. Non-pharmacological nursing interventions (hydration, quiet environment, supportive reorientation) are indicated.

Score 8 – 14 (Moderate): Indicates developing autonomic instability. Protocol-driven symptom-triggered benzodiazepine dosing (e.g., Lorazepam 1–2 mg PO, Diazepam 10 mg PO, or Chlordiazepoxide 25–50 mg PO) is initiated.

Score ≥ 15 (Severe): Signals impending medical emergency. High risk for withdrawal seizures and Delirium Tremens. Requires prompt administration of higher-dose benzodiazepines, continuous telemetry, IV access, and frequent nursing reassessment (every 30 to 60 minutes).

Critical Nursing Contraindication: CIWA-Ar relies heavily on subjective patient self-report (e.g., headache, sensory disturbances). It CANNOT be validly scored in uncommunicative, intubated, or severely delirious patients. In such patients, nurses must rely on objective parameters (vital signs, diaphoresis, gross tremor, RASS scale).

COWS: Clinical Opiate Withdrawal Scale

The Clinical Opiate Withdrawal Scale (COWS) is an 11-item clinician-administered instrument that quantifies the severity of opioid withdrawal.

  • COWS Item Parameter Breakdown
  • Resting Heart Rate: (0 = ≤80 bpm; 1 = 81–100 bpm; 2 = 101–120 bpm; 4 = >120 bpm)
  • Sweating: (0 = None; 1 = Flushed/moist; 2 = Beads of sweat; 3 = Drenching sweat)
  • Restlessness: (0 = Able to sit still; 1 = Frequent shifting; 3 = Unable to sit still; 5 = Pacing/thrashing)
  • Pupil Size: (0 = Normal/pinned; 1 = Slightly dilated; 2 = Moderately dilated; 5 = Extremely dilated)
  • Bone or Joint Aches: (0 = None; 1 = Mild; 2 = Severe/rubbing joints; 4 = Unable to sit due to severe ache)

Runny Nose or Tearing: (0 = None; 1 = Nasal stuffiness; 2 = Frequent sniffling/tearing; 4 = Constant running nose/tears)

GI Upset: (0 = Normal; 1 = Stomach cramps; 2 = Nausea/loose stool; 3 = Vomiting/diarrhea; 5 = Severe vomiting/diarrhea)

  • Tremor (hands): (0 = None; 1 = Slight; 2 = Visible; 5 = Gross tremor or muscle twitching)
  • Yawning: (0 = None; 1 = 1–2 times during assessment; 2 = 3+ times; 4 = Constant yawning)
  • Anxiety or Irritability: (0 = None; 1 = Mild; 2 = Perceptible; 4 = Severe/impairing)
  • Gooseflesh Skin (Piloerection): (0 = Smooth; 3 = Piloerection visible/goosebumps)
  • COWS Severity Stratification
  • 5 – 12: Mild opioid withdrawal
  • 13 – 24: Moderate opioid withdrawal
  • 25 – 36: Moderately severe opioid withdrawal
  • > 36: Severe opioid withdrawal
  • Buprenorphine Induction & Precipitated Withdrawal

Buprenorphine is a high-affinity partial mu-opioid agonist . If administered while full-agonist opioids (e.g., heroin, fentanyl, oxycodone) still occupy mu receptors, buprenorphine rapidly displaces the full agonist, abruptly dropping receptor activation and causing precipitated withdrawal .

To prevent precipitated withdrawal, CARN nurses enforce strict induction protocols:

Buprenorphine induction MUST NOT begin until the patient exhibits objective, moderate opioid withdrawal defined as a COWS score of at least 8 to 12 (preferably ≥12).

For short-acting opioids (heroin, oxycodone), wait at least 12–24 hours after last use.

For long-acting opioids (methadone), wait at least 48–72 hours after last use (and ensure COWS ≥12–14) due to prolonged tissue accumulation.

Loading diagram... Buprenorphine Induction Protocol & Precipitated Withdrawal Decision Tree